Fiasp (a niacinamide and L-arginine containing insulin aspart) has an onset that is 5 minutes faster than standard insulin aspart, whereas Lyumjev (a treprostinil and citrate containing insulin lispro) has an onset that is 11 minutes faster than standard insulin lispro in individuals with type 1 diabetes.4 Although some closed-loop studies have shown small improvements in glucose outcomes with Fiasp5 and Lyumjev,6 outcomes have been inconsistent.7, , -10. Here, INS is linked to type 1 diabetes mellitus.